Pharmacyclics Reports Positive Clinical Results With Xcytrin for Treatment Of Brain Tumors and Other Cancers at ASCO Meeting
(PR Newswire)Pharmacyclics, Inc. today reported results from several clinical trials with its lead product, Xcytrin(R) Injection, demonstrating that the investigational agent is well tolerated and may have clinical utility in a variety of cancers, including glioblastoma multiforme, childhood gliomas, pancreatic cancer and brain metastases, i.e., tumors that have spread to the brain from another part of the body.- May 14 9:01 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010514/sfm036a.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines